Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth. Technically it is a nitrogen containing bisphosphonate that binds strongly to bone mineral and inhibits osteoclast-mediated bone resorption by targeting the mevalonate pathway enzyme farnesyl diphosphate synthase, which interferes with protein prenylation required for osteoclast function. The active substance is a white to off-white crystalline powder with good aqueous solubility relative to nonphosphonate drugs, low absolute oral bioavailability that is markedly reduced by food or divalent cations, and stability suitable for formulation as immediate release tablets; routine quality control uses HPLC or LC-MS based assays for assay and related substances, and solid state characterization includes XRPD and DSC for polymorph control.
Parent: Risedronic Acid
API specifications for risedronic acid and its sodium salt typically control both process-related and degradation impurities with quantitative limits established for manufacturing and release; representative limits commonly applied are individual specified impurities not greater than 0.3%, individual unspecified impurities not greater than 0.1%, and total impurities not greater than 1.0 to 1.5%, with particular emphasis on positional isomers and hydrolysis products (positional isomer limits often set around 0.2 to 0.3% and hydrolysis degradants up to 0.5% where applicable). Additional quality attributes include heavy metals below 20 parts per million, residual solvents controlled per ICH Q3C (for example methanol class II limits) and water content typically limited to 2.0% or lower depending on the salt form and stability profile. Identification and quantitation of related compounds are normally performed by validated HPLC or LC-MS methods with system suitability criteria and impurity reference standards.
Risedronic acid, often used as its sodium salt risedronate sodium, is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption and is indicated for treatment and prevention of osteoporosis and for Paget’s disease of bone; it is administered orally and shows low oral bioavailability which is reduced by food and certain cations.
Risedronic acid binds to hydroxyapatite in bone and is internalized by osteoclasts where it inhibits farnesyl diphosphate synthase in the mevalonate pathway, preventing prenylation of small GTPases and disrupting osteoclast function leading to reduced bone resorption.
Impurities are controlled via validated synthetic route controls, purification steps and in-process testing, with release specifications typically limiting individual specified impurities to about 0.3%, unspecified impurities to about 0.1%, and total impurities to about 1.0 to 1.5%, alongside limits for heavy metals, residual solvents and water content.
Routine methods include reversed-phase HPLC with appropriate derivatization or ion-pair techniques and UV or MS detection, LC-MS for structural confirmation of related substances, and orthogonal techniques such as NMR, XRPD and DSC for identity and solid state characterization.
The API and formulated tablets are typically stored in a cool, dry place protected from moisture and light, with humidity and temperature ranges controlled per stability data; packaging and storage conditions are selected to keep water content and degradation products within specified limits.
